NEW YORK and LONDON, March 7th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics to Present at the 29th Annual ROTH Conference
Press Release
Akari Therapeutics to Attend Upcoming Investor Conferences in February
NEW YORK and LONDON, January 31st, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics to Attend Upcoming Investor Conferences in February
Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
NEW YORK and LONDON, January 4th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its …
[Read more...] about Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans
Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH
NEW YORK and LONDON, January 3rd, 2017 Phase II trial in eculizumab resistant PNH expected to expand into US Akari Therapeutics (NASDAQ: AKTX), an …
Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins
NEW YORK and LONDON, December 5th, 2016 - Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing- -PAS-Coversin pre-clinical …
